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Calcitonin gene-related peptide (CGRP) is one of the most potent microvascular vasodila-
tors identiﬁed to date. Vascular relaxation and vasodilation is mediated via activation of
the CGRP receptor. This atypical receptor is made up of a G protein-coupled receptor
called calcitonin receptor-like receptor (CLR), a single transmembrane protein called recep-
tor activity-modifying protein (RAMP), and an additional protein that is required for Gas
coupling, known as receptor component protein (RCP). Several mechanisms involved in
CGRP-mediated relaxation have been identiﬁed.These include nitric oxide (NO)-dependent
endothelium-dependent mechanisms or cAMP-mediated endothelium-independent path-
ways; the latter being more common. Subarachnoid hemorrhage (SAH) is associated with
cerebral vasoconstriction that occurs several days after the hemorrhage and is often fatal.
The vasospasm occurs in 30–40% of patients and is the major cause of death from this
condition.The vasoconstriction is associated with a decrease in CGRP levels in nerves and
an increase in CGRP levels in draining blood, suggesting that CGRP is released from nerves
to oppose the vasoconstriction.This evidence has led to the concept that exogenous CGRP
may be beneﬁcial in a condition that has proven hard to treat. The present article reviews:
(a) the pathophysiology of delayed ischemic neurologic deﬁcit after SAH (b) the basics
of the CGRP receptor structure, signal transduction, and vasodilatation mechanisms and
(c) the studies that have been conducted so far using CGRP in both animals and humans
with SAH.
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INTRODUCTION
In the US, over 30,000 persons each year experience a subarach-
noid hemorrhage (SAH). Whereas intracranial aneurysms are
found in 2−5% of all autopsies, the incidence of rupture is
only 2−20/100,000 individuals/year (Ingall et al., 2000). SAH is
more frequent in women than men (3:2 ratio) over the age of
40, but the reverse is the case in those younger than 40 (The
ACROSS Group, 2000; Ohkuma et al., 2002). Peak rupture rates
occur between the ages of 50 and 60 years (The ACROSS Group,
2000; Ohkuma et al., 2002). Intracranial aneurysms account for
approximately 85% of cases of non-traumatic SAH, whereas 10%
have the pattern of non-aneurysmal perimesencephalic hemor-
rhage, a relatively harmless condition (van Gijn et al., 2007). The
other causes include bleeding from other vascular malformations,
moyamoya syndrome, coagulopathy, and, rarely, extension of an
intracerebral hematoma (van Gijn et al., 2007). In up to 15%,
no source of bleeding is identiﬁed (Kim et al., 2012). Approxi-
mately 10−15%of patients die before receivingmedical treatment
from the initial bleed or its immediate complications (Huang
and van Gelder, 2002) and over 40% of hospitalized patients
die within 1 month of the event (Ingall et al., 2000). Those
that survive the initial bleed are at risk for a number of sec-
ondary insults including rebleeding (Winn et al., 1977; Ohkuma
et al., 2001), hydrocephalus, and cerebral vasospasm (van Gijn
et al., 2007).
Calcitonin gene-related peptide (CGRP) is one of the most
potentmicrovascular vasodilator peptides identiﬁed to date. In the
cerebral circulation, CGRP is released from sensory ﬁbers origi-
nating in the trigeminal ganglia and acts to dilate cerebral vessels
(McCulloch et al., 1986). CGRP has been found to be at least 1,000
times more potent than acetylcholine, substance P, ATP, adeno-
sine, and 5-hydroxytriptamine, and 10−100 times more potent
than the β-adrenergic agonist isoprenaline. Consequently, a dose
of 15 pmol injected into human skin produces an erythema that
lasts for 5−6 h (Brain et al., 1985). As we discuss later, CGRP has a
particularly potent vasodilator activity in the cerebral circulation,
rendering it a promising agent for the treatment of SAH-triggered
cerebral vasospasm.
In the present review, we summarize the etiology and therapy
of cerebral vasospasm, the biology of CGRP and its receptors,
and review the role of CGRP as a treatment in SAH-associated
vasospasm in both animals and humans.
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CEREBRAL VASOSPASM AFTER SAH
DEFINITIONS
Throughout the literature, authors have used various means of
deﬁning vasospasm including terms like angiographic vasospasm,
symptomatic vasospasm, and delayed cerebral ischemia (DCI).
Angiographic vasospasm is a narrowing of the lumen of the
major cerebral arteries, which is usually focal but may be dif-
fuse. Vasospasm has its onset usually on day 3 after SAH, is
maximal at days 6–8, and usually lasts for 2–3 weeks (Wilkins,
1990). Symptomatic vasospasm is characterized by the insidious
onset of confusion and decreased level of consciousness, fol-
lowed by focal motor and/or speech impairments. It is mainly
a diagnosis of exclusion, when clinical deterioration occurs and
hydrocephalus, rebleeding, hypoxia, and metabolic abnormalities
have been ruled out. DCI is deﬁned as symptomatic vasospasm,
infarction attributable to vasospasm, or both (Frontera et al.,
2009). Although about 70% of patients may develop arterial nar-
rowing, only 30%will manifest neurological deﬁcits. The outcome
of DCI itself is death in about one-third and permanent deﬁcit
in another third (Dorsch, 1995). In the present review the term
vasospasm is deﬁned as arterial vessel narrowing.
VASOSPASM PATHOPHYSIOLOGY
Nitric oxide
Loss of the biological effect of nitric oxide (NO) is considered
to play a pivotal permissive role in the development of cere-
bral vasospasm. The principal effect of NO on cerebral vessels
is the relaxation of vascular smooth muscle cells, with decreased
bioavailability of NO being implicated in the formation of SAH-
induced vasospasm. The depletion of NO has been assumed to
occur via several mechanisms in the setting of SAH. First, due
to its high afﬁnity for hemoglobin (Hb), NO is scavenged by Hb
released during the breakdown of subarachnoid blood (Goretski
and Hollocher, 1988; Ignarro, 1990). Second, it is possible that
the production of NO is decreased in SAH, as a result of the
down-regulation of endothelial NO synthase (eNOS) and neu-
ronal NOS (nNOS; Pluta, 2005). This is supported by studies that
revealed the down-regulation/dysfunction of eNOS, and loss of
nNOS in spastic arteries after SAH (Hino et al., 1996; Pluta et al.,
1996), aswell as theﬁnding that levels of asymmetric dimethylargi-
nine (ADMA), an endogenous inhibitor of eNOS, are elevated in
the setting of cerebral vasospasm (Jung et al., 2004). Third, NO
may reverse the effects of the potent vasoconstrictor endothelin-1
(ET-1; Thomas et al., 1997). Therefore, in the setting of decreased
NO levels, the balance of vasodilator and vasoconstrictor inﬂu-
ences is altered, and the relatively increased actions of ET-1 can
potentiate cerebral vasospasm.
Endothelin-1
ET-1 is an extremely potent vasoconstrictor. In the brain, it is
primarily produced by endothelial cells in response to ischemia,
though it can also be produced by neurons, astrocytes, and
activated leukocytes (Fassbender et al., 2000; Chow et al., 2002;
Dumont et al., 2003). Levels of ET-1 are high in the plasma and
cerebrospinal ﬂuid (CSF) of SAH patients, correlate with the per-
sistence of cerebral vasospasm (Seifert et al., 1995; Juvela, 2000),
and decline in the absence of vasospasm (Seifert et al., 1995).
Conversely, the administration of ET-1 antagonists or endothe-
lin converting enzyme inhibitors prevents vasospasm (Kwan et al.,
2002; Macdonald et al., 2008). Lastly, ET-1 induces NADPH oxi-
dase expression and oxidative stress in human endothelial cells
(Duerrschmidt et al., 2000).
Inﬂammation
Expression of adhesion molecules facilitates leukocyte adher-
ence to the endothelium. Adhesion molecules, such as ICAM-1,
VCAM-1, and E-selectin, have been found to be elevated in the
CSF of patients with SAH and in blood vessel walls exposed to
clot (Polin et al., 1998; Dumont et al., 2003). Leukocytes can con-
tribute to vasospasmby promoting free radical formation thatmay
evoke endothelial dysfunction (Grisham et al., 1998; Sullivan et al.,
2000), and by producing a variety of vasoactive substances, includ-
ing ET-1 and cytokines (Fassbender et al., 2000). Several cytokines
have been found to be up-regulated in cerebral vasospasm, includ-
ing TNF-alpha, IL-1, IL-6, and IL-8 (Hirashima et al., 1997;
Fassbender et al., 2001; Takizawa et al., 2001).
Oxidative stress
Oxyhemoglobin (OxyHb)may catalyze generation of reactive oxy-
gen species (ROS). Free radicals are considered toplay a pivotal role
in cerebral vasospasm through various mechanisms. First, they
can initiate lipid peroxidation, whose products, lipid peroxides,
are capable of producing vasospasm and damaging the structure
of arteries (Lin et al., 2006). Second, it has been hypothesized that
ROS can activate the protein kinase C (PKC) pathway directly and
indirectly, through enhancement of the metabolism of membrane
phospholipids resulting from peroxidative damage. This, in turn,
can lead to vasospasm (Asano and Matsui, 1999). Other possible
vasoactive compounds are bilirubin oxidation products (BOXes).
Once bilirubin is formed, it is subsequently oxidized into BOXes,
reaching maximum concentrations during the peak vasospasm
period of 4–11 days. They are thought to be potentiators of cere-
bral vasospasm once it has been initiated, rather than primary
initiators (Clark and Sharp, 2006).
Hemoglobin
A large body of evidence suggests that OxyHb, the ferrous form
of hemoglobin, released from lysed erythrocytes, is a media-
tor of vasospasm. More speciﬁcally, OxyHb causes prolonged
contraction of isolated cerebral arteries (Toda et al., 1991), and
intracisternal injections of this agent result in cerebral vasospasm
(Macdonald et al., 1991). Indeed, the presence of OxyHb in the
CSF of patients after SAH and the extent of hemorrhage are
correlated with the distribution, severity, and time course of
vasospasm (Mayberg et al., 1990). Ferrous hemoglobin released
from subarachnoid clot could lead to delayed arterial narrowing
by a number of mechanisms, such as scavenging or decreased pro-
duction of NO (Pluta, 2005), free radical production,modiﬁcation
of K+ and Ca2+ channels (Ishiguro et al., 2008), differential up-
regulation of genes (Vikman et al., 2006), and activation of the
Rho/Rho kinase and PKC pathways (Wickman et al., 2003).
Intracellular Ca2+
Vasospasm can be regarded as an abnormal and prolonged con-
traction of vascular smooth muscle. The intracellular free Ca2+
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level plays a pivotal role in the regulation of smooth muscle
contractility (Horowitz et al., 1996). Following SAH, changes
have been reported in the electrical properties of smooth mus-
cle cells of small diameter cerebral arteries leading to enhanced
Ca2+ inﬂux, vasoconstriction, and decreased cerebral blood
ﬂow (Koide et al., 2011). Cerebral arteries from healthy ani-
mals express only L-type voltage-dependent Ca2+ channels.
Expression of an additional type of voltage-dependent Ca2+
channels (R-type) occurs after SAH, leading to increased Ca2+
channel density, increased Ca2+ inﬂux, and vasoconstriction
(Ishiguro et al., 2005).
Cortical spreading depolarization
This is a pathogenetic process that has attracted much atten-
tion lately. The term “cortical spreading depolarization” describes
the wave of near-complete neuronal depolarization and neu-
ronal swelling in the brain that is ignited when passive cation
inﬂux across the cellular membranes exceeds ATP-dependent
Na+ and Ca2+ pump activity. The cation inﬂux is followed
by water inﬂux and shrinkage of the extracellular space by
∼70% (Dreier et al., 2009). Although the ignition of corti-
cal spreading depolarization occurs passively, driven by elec-
trical and diffusion forces, energy consumption paradoxically
increases since Na+ and Ca2+ pumps are immediately acti-
vated to correct the intracellular Na+ and Ca2+ surge. As a
consequence, regional cerebral blood ﬂow increases during the
neuronal depolarization phase. The opposite of this physiolog-
ical hemodynamic response to cortical spreading depolarization
is termed “the inverse hemodynamic response,” and occurs
when there is local dysfunction of the microvasculature. With
the inverse response, severe microvascular spasm instead of
vasodilatation is coupled to the neuronal depolarization phase,
and the term “cortical spreading ischemia” describes the cor-
tical spreading depolarization-induced perfusion deﬁcit (Dreier
et al., 2009).
Neurogenic factors
The cerebral arteries have sympathetic, parasympathetic, and
sensory innervation. It has been postulated that SAH causes a
derangement of neuronal regulatory mechanisms, which in turn
leads to vascular smoothmuscle contraction. The vasoconstriction
is associated with a decrease in CGRP levels in cerebral perivascu-
lar nerves (Edvinsson et al., 1991) and an increase in CGRP levels
in blood draining from the external jugular vein (Juul et al., 1990),
suggesting that CGRP is released antidromically from trigeminal
sensory perivascular nerves to oppose the vasoconstriction. This
evidence has led to the concept that administration of CGRP may
be beneﬁcial in SAH-associated vasospasm. The molecular char-
acteristics of CGRP and its use as a treatment option in SAH are
reviewed in Sections “Calcitonin Gene-related Peptide Biology”
and “Calcitonin Gene-related Peptide and SAH,” respectively, of
the present article.
TREATMENT OF VASOSPASM
The management of vasospasm involves routine “prophylactic”
measures as well as more aggressive interventions, reserved for
situations where there are signs or symptoms of DCI.
Hemodynamic therapy
The use of triple-H therapy (hypervolemia, hypertension, and
hemodilution) stems from numerous clinical observations noting
improvement in patients’ clinical symptoms following induced
hypertension and volume expansion (Kosnik and Hunt, 1976;
Kassell et al., 1982). The relative contribution of each compo-
nent is debated. However, there are many uncertainties for the
use of prophylactic hemodynamic therapy following SAH. Two
studies randomly assigned normovolemic or hypervolemic ther-
apy to patients and reported no difference in the incidence of DCI
between groups (Lennihan et al., 2000; Egge et al., 2001).
Nimodipine
Nimodipine is safe, cost-effective, and reduces the risk of poor
outcome and secondary ischemia (Neil-Dwyer et al., 1987; Welty,
1987; Kostron et al., 1988; Mee et al., 1988), but has very mod-
est effects. It is used prophylactically in all patients with SAH.
Its precise mechanism of action remains unclear. Despite being
shown to reduce the incidence of DCI and cerebral infarction in
clinical trials, it has negligible effects on angiographic vasospasm;
nimodipine may be neuroprotective by blocking Ca2+ inﬂux at a
neuronal level (Al-Tamimi et al., 2010).
Intracisternal thrombolysis
A meta-analysis looking at a total of 652 patients who were treated
with intracisternal thrombolytics concluded that thrombolytic
therapy had a statistically signiﬁcant beneﬁcial effect. However, the
authors acknowledged the lack of large, randomized prospective
trials (Amin-Hanjani et al., 2004).
Endovascular techniques
Endovascular techniques frequently play a role in the aggressive
treatment of vasospasm. They include transluminal angioplasty
and intra-arterial infusion of vasodilators (papaverin, nicardip-
ine, verapamil, etc.; Brisman et al., 2006). Transluminal balloon
angioplasty is very effective at reversing angiographic spasm of
large proximal vessels and produces a sustained reversal of arte-
rial narrowing (Brisman et al., 2006; Jestaedt et al., 2008). The
optimal timing of angioplasty in relation to medical therapy
is uncertain. Major complications occur in ∼5% of proce-
dures and include vessel rupture, occlusion, dissection, hemor-
rhagic infarction, and hemorrhage from unsecured aneurysms
(Zwienenberg-Lee et al., 2006).
Statins
Statins have been shown to possess cholesterol-lowering-
independent pleiotropic effects in different clinical settings,
including a decrease in the incidence and duration of severe
vasospasm as well as a reduction in the mortality rate after
SAH (Lynch et al., 2005; Tseng et al., 2005, 2007). Statins are
thought to be beneﬁcial in the prevention of cerebral vasospasmby
down-regulating inﬂammation and up-regulating the expression
of eNOS and therefore NO (Sugawara et al., 2011).
Other treatments
Clazosentan, an endothelin receptorA (ETA) antagonist decreased
the incidence of severe vasospasm, DCI and new infarcts seen on
CT scans in a dose-dependent fashion. However, CONSCIOUS 1
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study (a phase 2 trial) did not show a reduction in patient mor-
tality, though the study was underpowered for this endpoint (the
primary end point of this study wasmoderate or severe vasospasm
within 14 days; Macdonald et al., 2008). CONSCIOUS 2 study (a
phase 3 trial) included 1157 patients and its primary composite
end point comprised all-cause mortality and vasospasm related
morbidity. This study showed that clazosentan at 5 mg/h had no
signiﬁcant effect on mortality and vasospasm-related morbidity
or functional outcome (Macdonald et al., 2011).
Erythropoietin (EPO) has also been examined in the setting of
cerebral vasospasm. Apart from being potentially neuroprotective,
EPO may play a role in preventing vasospasm by increasing the
phosphorylation of eNOS (Santhanam et al., 2005), a potentially
important mechanism for increasing NO production.
A recent randomized controlled trial (MASH 2) including 1204
patients did not show any beneﬁt from intravenous (i.v.) magne-
sium sulfate administration in clinical outcome after aneurysmal
SAH (Dorhout Mees et al., 2012).
Other drugs under investigation are tirilazad, a free radical
scavenger (Haley et al., 1997), fasudil, a Rho-kinase inhibitor
that inhibits vascular smooth muscle contraction (Shibuya et al.,
1992), sodium nitrite, an NO donor (Pluta et al., 2005) and cister-
nal placement of prolonged-release nicardipine-loaded polymers
(Kasuya et al., 2005).
CALCITONIN GENE-RELATED PEPTIDE BIOLOGY
CALCITONIN GENE-RELATED PEPTIDE
Calcitonin gene-related peptide is expressed in a subgroup of small
neurons in the dorsal root, trigeminal, and vagal ganglia, which
respond to noxious, thermal, or visceral input. These peptider-
gic neurons use L-glutamate as their primary neurotransmitter
and project to the dorsal horn, trigeminal nucleus caudalis, or
nucleus of the solitary tract. CGRP increases neurotransmit-
ter release and neuronal responsiveness to noxious stimulation
at all these levels, which leads to central sensitization underly-
ing chronic pain states (Benarroch, 2011). CGRP can also be
released antidromically in the periphery, eliciting vasodilatation
as a component of neurogenic inﬂammation. CGRP may be
involved in the pathophysiology of inﬂammatory and neuropathic
pain. Involvement of CGRP in migraine headache has led to the
development of CGRP antagonists for treatment of this disorder
(Benarroch, 2011).
Calcitonin gene-related peptide is a 37-amino acid neuropep-
tide that was identiﬁed in 1982 by molecular biological techniques
in the thyroid of aging rats and medullary thyroid carcinomas
in humans, which were found to contain an alternative peptide
product from the calcitonin gene (Amara et al., 1982). CGRP, in
common with other members of this peptide family, is derived
from the calcitonin gene. Other members of this family include
adrenomedulin (AM), which is a potent vasodilator, amylin
(AMY), which is important for maintaining glycemic control, and
calcitonin, which contributes to calcium metabolism (Hay, 2007).
CGRP exists in two forms, named αCGRP and βCGRP. While
these two isoforms share the same biological activities, and differ
by only three amino acids in the human (Steenbergh et al., 1985,
1986), they are formed from two distinct genes, which share>90%
homology, at different sites on chromosome 11. CALC I gene
forms calcitonin and αCGRP, whereas CALC II forms βCGRP
(Alevizaki et al., 1986). αCGRP synthesis is caused by alterna-
tive splicing of the calcitonin gene (Amara et al., 1982; Figure 1).
βCGRP is known to be transcribed from its own distinct gene
(Steenbergh et al., 1985, 1986). The majority of CGRP within the
body is αCGRP and primarily expressed in the peripheral and
central nervous system. βCGRP is mainly expressed in the gut
(Mulderry et al., 1988). However, it has also been identiﬁed in
the central nervous system, pituitary, thyroid, and in medullary
thyroid carcinoma as a major CGRP form together with αCGRP
(Petermann et al., 1987).
Data fromNMRstudies suggest that CGRP consists of a charac-
teristic N-terminal disulﬁde bridge-linked loop between cysteines
Cys2 and Cys7, followed by an alpha-helix in amino acids Val8-
Arg18 (Breeze et al., 1991). The next domain at residues 19–27
forms a hinge region (Conner et al., 2002). The C-terminus lies
at residues 28–37, and contains two turn regions which form a
putative binding epitope (Carpenter et al., 2001). It appears that
the N-terminal cyclic portion of the CGRP molecule, containing a
ring structure with a disulﬁde bond, is essential for agonistic activ-
ity (Maggi et al., 1990). It is interesting to note that the C-terminal
fragment, CGRP8−37, is devoid of any agonist activity at CGRP
receptors, although it behaves as a competitive antagonist against
the intact peptide (Chiba et al., 1989).
Calcitonin gene-related peptide is widely distributed in the cen-
tral and peripheral nervous systems, primarily in sensory ﬁbers
that are closely associatedwith blood vessels (Uddman et al., 1986).
CGRP is often co-localized with other peptides in these ﬁbers,
especially the tachykinin substance P (Uddman et al., 1986). In the
cerebral circulation, CGRP is released from sensory ﬁbers origi-
nating in the trigeminal ganglia and acts to dilate cerebral vessels
(McCulloch et al., 1986). In the gut, CGRP is also released from
spinal afferents, where it dilates mucosal blood vessels and may
protect against the acidic environment (Holzer, 2000). CGRP-
containing ﬁbers also innervate coronary arteries of the heart
(Gulbenkian et al., 1993).
The regulation of CGRP production is poorly understood. At
a cellular level, nerve growth factor (NGF) up-regulates CGRP
via the Ras/Raf/mitogen-activated protein kinase kinase-1 (MEK-
1)/p42/p44 pathway (Freeland et al., 2000).
In the human circulation, CGRP has a half-life of approxi-
mately 7–10 min (Kraenzlin et al., 1985; Struthers et al., 1986).
Regarding its metabolism, it seems that there is not an obvious
mechanism, and it is probably broken down via a number of
routes. First, mast cell tryptase has a potent effect in cleaving
CGRP into inactive fragments, both in vivo and in vitro. More
speciﬁcally, if both CGRP and substance P are released simulta-
neously, then CGRP could be inactivated by enzymes (tryptases),
released by mast cells in response to substance P. This mechanism
has been demonstrated in skin (Brain and Williams, 1988, 1989).
Second, a matrix metalloproteinase II has the ability to metabolize
CGRP and remove its vasodilator activity (Fernandez-Patron et al.,
2000). Third, Sams-Nielsen et al. (2001) have provided evidence
that CGRP is taken back up into sensory nerve terminals after
repolarization in vitro. Finally, in the CSF, αCGRP is degraded by
an endopeptidase that cleaves the peptide at the Leul6-Ser17 bond
(Le Greves et al., 1989).
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FIGURE 1 |Tissue-specific expression of the calcitonin gene by alternative splicing. Splicing of alternative exons leads to two different mRNAs. The mRNA
encoding calcitonin is found predominantly in the thyroid C cell; the mRNA encoding a CGRP is found predominantly in the hypothalamus and other nervous
tissue. CGRP, calcitonin gene related peptide; mRNA, messenger RNA; CCP, calcitonin carboxyl-terminal peptide. From Amara et al. (1982), with permission.
STRUCTURE OF CGRP RECEPTORS
Many peptides, including the CGRP family, mediate their actions
via G protein-coupled receptors (GPCR). The GPCRs form the
largest family of cell-surface proteins that are capable of interact-
ing with an extracellular stimulus and transducing that stimulus
to produce a reaction inside a cell (Pierce et al., 2002). All GPCRs
have seven transmembrane spanning domains, an extracellular
N-terminus and an intracellular C-terminus and can be divided
into three families based on signature amino acid sequences.
Family A is the largest and generally binds small molecules and
short peptides. Receptors in this class have been studied exten-
sively, including photoreceptor rhodopsin, as well as adrenergic
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and olfactory receptors. Family B receptors bind larger peptides
in the range of 27 to approximately 50 amino acids (secretin,
glucagons, VIP, etc.). These receptors mediate the actions of
CGRP and related peptides (Poyner et al., 2002; Hoare, 2005).
Family C receptors include glutamate and GABAB receptors
(Pierce et al., 2002).
Calcitonin receptor-like receptor (CLR),which belongs to fam-
ily B of the GPCRs, comprises the main functional unit of the
CGRP receptor (Figure 2). It was not until McLatchie’s work
(McLatchie et al., 1998) was published that it was recognized that
a novel family of single transmembrane domain proteins, called
receptor activity-membrane proteins (RAMP), were required to
allow CLR to bind peptide and transduce signal. Three RAMPs
have been identiﬁed so far (RAMP1, RAMP2, and RAMP3).
Each RAMP has a single transmembrane-spanning domain, a
short intracellular C-terminal tail (∼9 amino acids) and a long
extracellular-terminus (∼100 amino acids;McLatchie et al., 1998).
As a result of CLR and calcitonin receptor (CTR) interactions
with RAMP, the International Union of Pharmacology (IUPHAR)
nomenclature recognizes that CGRP interacts with CLR/RAMP1
(CGRP1) receptors, whereas AM interacts with CLR/RAMP2
(AM1) orCLR/RAMP3 (AM2) receptors. TheCTRwithout RAMP
is sufﬁcient for calcitonin binding, but CTR with RAMP 1, 2, or 3
are AMY1, AMY2, and AMY3 receptors, respectively (Poyner et al.,
2002). The discovery of RAMPs has led to evolution of our under-
standing of how receptor diversity is implemented, providing a
novel mechanism for generating receptor subtypes within a subset
of family B GPCRs (Sexton et al., 2006).
The primary function of CLR is thought to be related to ligand
binding, whereas the RAMP molecule plays a crucial role in recep-
tor trafﬁcking to the membrane and determination of receptor
pharmacology. The RAMP family regulate the glycosylation and
transport of the CLR. However, they are not CGRP receptors by
themselves (McLatchie et al., 1998; Sexton et al., 2009). Terminal
glycosylation of the receptor and transit from the endoplasmic
reticulum/Golgi apparatus to the cell surface require interaction
of CLR with RAMP (Sexton et al., 2009).
Calcitonin gene-related peptide receptor activation is known to
involve several crucial elements, in common with other GPCRs,
such as the presence of a proline “kink” in transmembrane helix
(TM)6 (Conner et al., 2005), and a putative ‘DRY’motif equivalent
(Conner et al., 2007), similar to family A GPCRs. There is also
evidence suggesting stabilization of the CLR interaction with G
“alpha” s (Gas) by another 17kDa intracellular membrane protein,
called RCP (Evans et al., 2000).
The existence of two receptors, CGRP1 and CGRP2, was orig-
inally proposed in the late 1980s, with the CGRP1 receptor being
the predominant mediator of cardiovascular effects. This receptor
classiﬁcation was developed as a consequence of pharmacologi-
cal studies carried out with different agonists and antagonists in
a range of tissue preparations, especially the positive inotropic
effect in the guinea pig or rat atrium for determination of CGRP1
receptor activity, and the inhibition of electrically evoked twitch
responses in the rat vas deferens for determination of CGRP2
receptor activity (Dennis et al., 1989, 1990; Dumont et al., 1997).
In general, receptors that can be antagonized by the 30-amino acid
fragment of CGRP, CGRP8−37, with an approximate pA2 value of
7.0 are designated as CGRP1 receptors, while those that CGRP8−37
block with a pA2 of 6.0 or less are classiﬁed as CGRP2 receptors
(Quirion et al., 1992; Poyner, 1995). However, it is questionable
whether the CGRP2 receptor is a single receptor type or whether
it is, in fact, explained by multiple molecular entities (Hay, 2007).
FIGURE 2 | Structure of CGRP receptor. CGRP receptor components and
important residues for receptor signaling and internalization. The CGRP
receptor is formed by CLR (blue), RAMP1 (yellow), and RCP (orange).
Functionally important residues are shown as single letter abbreviations.
CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor;
RAMP, receptor activity-modifying protein; RCP, receptor component protein;
C′, C-terminal; EC, extracellular loop; ICL, intracellular loop; N′, N-terminal;
TM, transmembrane. FromWalker et al. (2010), with permission.
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In contrast, CGRP1 is a well-deﬁned receptor type consisting of
CLR and RAMP1.
SIGNAL TRANSDUCTION OF CGRP RECEPTOR
Several mechanisms involved in CGRP-mediated vasorelax-
ation have been identiﬁed. These mechanisms include either
NO-dependent endothelium-dependent mechanisms or cAMP-
mediated endothelium-independent pathways. The most com-
monpathway isNO- and endothelium-independent. Activation of
the CGRP receptor is generally accepted to result in Gas-mediated
activation of adenylate cyclase, with a subsequent increase in
cAMP and activation of protein kinase A (PKA). In the absence
of endothelium, CGRP is able to cause relaxation, suggesting it
must directly act on the smooth muscle cells to stimulate adeny-
late cyclase (Edvinsson et al., 1985, 1998; Crossman et al., 1990).
The resulting rise in cAMP then activates PKA, which phospho-
rylates and opens up ATP-sensitive K+ channels, thus leading to
relaxation (Figure 3A; Nelson et al., 1990).
Endothelium-independent relaxation to CGRP occurs in the
majority of tissues examined to date. Exceptions include the rat
aorta, where the relaxation to CGRP occurs only in the pres-
ence of an intact endothelium and is attenuated by inhibitors
of NO synthase, implying an NO-dependent mechanism (Brain
et al., 1985; Gray and Marshall, 1992a,b). A signiﬁcant increase in
both cAMP and cGMP occurs and is also dependent on the pres-
ence of endothelium (Gray and Marshall, 1992a). This implicates
the release of NO from the endothelium, which then relaxes the
smooth muscle cells through activation of guanylate cyclase and
accumulation of cGMP. Moreover, it has been shown that cAMP
is able to stimulate eNOS activity, leading to increased synthe-
sis and release of NO (Ferro et al., 1999; Queen et al., 2000). The
activation of eNOS via cAMP is probably mediated via PKA, as
a study demonstrated that various protein kinases can phospho-
rylate and activate eNOS (Butt et al., 2000). It is a possibility that
CGRP causes an increase in cAMP in endothelial cells, which leads
to PKA activation. PKA, in turn, activates eNOS, which results in
NO release, and thus relaxation of the smoothmuscle (Figure 3A).
There is some evidence for Gai/o signaling by the CGRP recep-
tor, which is traditionally identiﬁed by sensitivity to pertussis toxin
(PTX; Figure 3B). The CGRP-mediated stimulation of Ca2+ tran-
sients in rat nodose neurons and the activationof c-JunN-terminal
kinase (JNK) in SK-N-MC cells (which express endogenous CGRP
receptors) both displayed PTX sensitivity (Wiley et al., 1992; Disa
et al., 2000).
FIGURE 3 | CGRP receptor-mediated intracellular signaling. (A) Gas
signaling increases AC (green) activity, elevating intracellular cAMP, activating
PKA and subsequently many potential downstream effectors. (B)The CGRP
receptor might also couple to Gai/o, reducing AC (red) activity, decreasing
intracellular cAMP and reducing PKA activity. (C) CGRP signaling via Gaq
activates PLC-b, which cleaves PIP2 into IP3 and DAG, resulting in elevated
intracellular Ca2+ and PKC activation. (D)The CGRP receptor might also
utilize Ga-independent signaling, and Gβγ- or b-arrestin-mediated signaling
pathways. Arrows represent reported pathways; broken arrows represent
potential or inferred pathways. CGRP, calcitonin gene-related peptide; CLR,
calcitonin receptor-like receptor; Gα, α subunit of the G protein; NO, nitric
oxide; NOS, nitric oxide synthase; AC, adenylyl cyclase; cAMP, cyclic
adenosine monophosphate; PKA, protein kinase A; PKC, protein kinase C;
RCP, receptor component protein; AC, adenylate cyclase; ER, endoplasmic
reticulum; PIP2, phosphatidylinositol 4,5-bisphosphate; DAG, diacylglycerol.
FromWalker et al. (2010), with permission.
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The CGRP receptor may also be able to stimulate intracel-
lular activity through a different G protein. Aiyar et al. (1999)
reported that CGRPwas able to activate phospholipase C (PLC) in
HEK293 cells, leading to an increase in intracellular Ca2+ via inos-
itol trisphosphate (IP3) activity. This increase in Ca2+ occurred
concurrently with the stimulation of adenylyl cyclase and accumu-
lation of cAMP. Activation of PLC is considered to occur through
Gq/11α, rather than through Gαs, suggesting that the activated
CGRP receptor is able to interact with both types of G protein.
If this mechanism is present in endothelial cells, it provides an
alternative explanation for CGRP activation of eNOS (which is
traditionally considered to be dependent on Ca2+/calmodulin for
activation), independently of cAMP accumulation. The possibil-
ity that CGRP receptors may be coupled to phosphatidylinositol
turnover is supported by another study that found this secondary
messenger pathway in skeletalmuscle (Laufer andChangeux,1989;
Figure 3C).
Recently, Meens et al. (2012) reported that activated CGRP
receptors induce cyclic nucleotide-independent relaxation of vas-
cular smooth muscle cells in mesenteric resistance arteries and
terminate arterial effects of ET-1 via Gβγ. More speciﬁcally, CGRP
receptor activation causes cAMP production but the relaxation
of rat mesenteric resistance arteries induced by activation of this
receptor involves Gβγ and is not dependent on cAMP (Figure 3D).
Another study by Meens et al. (2010) discovered that CGRP
released from peri-arterial sensory motor nerves terminates long-
lasting vasoconstrictor effects of ET-1 by promoting dissociation
of ET-1/ETA-receptor complexes.
The CGRP receptor can also potentially activate other down-
stream signaling molecules, such as PKC and mitogen-activated
protein kinase (MAPK) cascades, such as p38, JNK, and extracel-
lular receptor activated kinase 1/2 (ERK ½; Walker et al., 2010).
CGRP receptor signaling is regulated by desensitization, internal-
ization, and trafﬁcking, which, as with other GPCRs, involves
GPCR kinases (GRK), β arrestin, and clathrin- and dynamin-
dependent endocytosis (Walker et al., 2010). Padilla et al. (2007)
proposed a mechanism by which endosomal endothelin con-
verting enzyme-1 (ECE-1) degrades CGRP in endosomes to
disrupt the peptide/receptor/β-arrestin complex, freeing inter-
nalized receptors from β-arrestins and promoting recycling and
resensitization, resulting in long-lasting vascular relaxing response
to CGRP.
CALCITONIN GENE-RELATED PEPTIDE AND SAH
PRELIMINARY OBSERVATIONAL STUDIES
An animal study of experimental SAH in rats revealed that the sen-
sory innervation of the cerebral circulation by CGRP-containing
ﬁbers appeared to be reduced after SAH (estimated by the number
of ﬁbers present), and there was also a larger vasodilating response
to CGRP in basilar arteries after SAH as compared to vessels from
control animals. The reduction in CGRP could be due to release
of the transmitter from the perivascular nerve terminals caused by
blood in the subarachnoid space (Edvinsson et al., 1990).
In another study (Edvinsson et al., 1991), the proximal parts
of the middle cerebral artery (MCA) were collected within 24 h
after death from ﬁve humans suffering SAH (5−10 days before-
hand) and from six subjects dying from myocardial infarction. In
humans who had died from SAH the level of CGRPwas nearly not
detectable, being in contrast to that seen in age and sex matched
subjects who had died of myocardial infarction. The trigemino-
cerebrovascular system was suggested by the authors to act as an
anti-vasoconstrictor system by releasing stored peptides, CGRP
being the most likely candidate.
Juul et al. (1995) measured CGRP levels with speciﬁc radioim-
munoassays (RIA) in patients with SAH, after operation with
aneurysm clipping and nimodipine treatment. They used sam-
ples taken either from the external jugular vein (n = 20) or from
the CSF (n = 14) during the postoperative course. They also used
samples from healthy volunteers. The degree of vasoconstriction
in the patients was monitored with Doppler ultrasound record-
ings. CGRP concentrations from the external jugular vein were
signiﬁcantly higher than from controls. Also, the CGRP level was
measurable in SAH CSF but not in CSF of controls.
Others (Tran Dinh et al., 1994) showed that the basal level of
endogenous CGRP in CSF was 0.77 nmol/L in rabbits. The CGRP
concentration peaked at 14 nmol/Lwithin 30min, and at 8 nmol/L
within 24 h, after SAH. They further showed that 3 days after SAH
the CGRP concentration in CSF declined to 3.5 nmol/L.
Nozaki et al. (1989a) produced a model of SAH by a single
injection of fresh autologous arterial blood into the cisternamagna
of dogs. Then, they examined changes of CGRP immunoreactivity
immunohistochemically in perivascular nerve ﬁbers of the large
pial arteries. CGRP in cerebrovascular nerve ﬁbers was suppressed
after SAH. The suppressionwas ﬁrst detected on the third day after
SAH, and was most marked during the 7th to 14th day. CGRP,
however, recovered to a normal level by the 42nd day after SAH.
Arienta et al. (1991) isolated the basilar artery from ﬁve rab-
bits subjected to SAH and ﬁve control animals. A mild or severe
vasospasm was observed in the basilar artery about 15 min after
injection of blood in the cisterna magna, while ﬂuorescence
immunohistochemistry revealed amarked decrease of the perivas-
cular nerves containing CGRP in the animals of the experimental
group, as compared to the control group.
EFFECTS OF CGRP ADMINISTRATION ON CEREBRAL VASOSPASM
AFTER EXPERIMENTAL SAH IN ANIMALS (Table 1)
Nozaki et al. (1989b) produced experimental SAH in 30 dogs by
injecting autologous arterial blood into the cisterna magna. They
used two models of injection: in the ﬁrst, single-injection model,
1 ml/kg of blood was injected on day 0, while 0.5 ml/kg of blood
was injected successively 48 h apart in the second, double-injection
model, on day 0 and day 2. The diameter of the basilar artery
was measured by angiography. The most marked constriction
of the basilar artery was seen on day 3 after SAH in the single-
injectionmodel and onday 7 in the double-injectionmodel.When
10−10 mol/kg of CGRP was administered intracisternally (i.c.) on
day 3 in the single-injection model, cerebral vasospasm reversed
completely. The effect began to appear 5 min after CGRP admin-
istration, continued for 4 h, and disappeared by 24 h after the
administration. When CGRP was administered at doses of 10−11
to 2 × 10−10 mol/kg on day 7 after SAH in the double-injection
model, the cerebral vasospasm was reversed in a dose-dependent
manner: 2 × 10−10 mol/kg of CGRP reversed the vasospasm
completely. The effect began to appear 5 min after the CGRP
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Table 1 | Studies of CGRP administration after experimental SAH in animals.
Reference Animal
model
Total sample size
(intervention/
control)
Way of CGRP
administration
CGRP dose Results Adverse events
Nozaki et al. (1989b) Dog 30 (22/8) i.c. 2 × 10−10 mol/kg Vasospasm was reversed
completely
AP and HR slightly
increased
Imaizumi et al. (1996) Rabbit 16 (8/8) i.c. 10−10 mol/kg Basilar artery dilated from 73 to
117%, signiﬁcantly larger than
67% in control (p < 0.01)
None
Toshima et al. (1992) Rabbit 41 (17/24) i.c./i.v. 100 ng/kg/min i.c./
100 ng/kg/min i.v.
Basilar artery diameter in either
i.v. or i.c. CGRP groups was
signiﬁcantly greater than that of
the respective control group
AP drop in i.v. CGRP
administration
Ahmad et al. (1996) Rabbit 45 (22/23) i.c. slow-release
tablet
24 or 153 μg Vasospasm was completely
reversed
None
Inoue et al. (1996) Monkey 10 (5/5) i.c. slow-release
tablet
1,200 μg Cerebral vasospasm was
signiﬁcantly ameliorated
None
Toyoda et al. (2000) Rabbit 16 (8/8) i.c. adenovirus-
mediated CGRP
gene transfer
NA Arterial diameter was similar
before and after SAH in CGRP
group
None
Satoh et al. (2002) Dog 20 (8/12) i.c. adenovirus-
mediated CGRP
gene transfer
NA Vasospasm was signiﬁcantly
reduced compared with the
control group
None
i.c., intra-cisternal; i.v., intravenous; AP, arterial pressure; HR, heart rate; SAH, subarachnoid hemorrhage; NA, non-applicable.
administration, continued for 4 h, and disappeared by 24 h. Of
note, when the amounts of CGRP mentioned above were admin-
istered i.c., both mean arterial blood pressure and heart rate were
only slightly increased and returned to the previous levels within
several minutes.
In a similar study by Imaizumi et al. (1996), experimental SAH
was produced by i.c. injection of arterial blood in rabbits. The
animals were treated with intrathecal administration of CGRP 3
days after SAH. The degree of vasospasm and the effect of CGRP
were evaluated angiographically by measuring the basilar artery
diameter. The basilar artery constricted to 73%of the pre-SAHval-
ues 3 days after SAH. Fifteen minutes after 10−10 mol/kg CGRP
injection, the basilar artery dilated from 73 to 117% (n = 8),
which was signiﬁcantly larger than 67.1% in the vehicle group
(n = 8; p < 0.01). At 6 h after 10−10 mol/kg CGRP injec-
tion, the basilar artery was still dilated to 90% (p < 0.05). In
the 10−11 mol/kg CGRP group, the basilar artery was dilated
to 87% (p < 0.05) 15 min after the injection. The injection of
10−12 mol/kg CGRP had no signiﬁcant effect. The dilatory effect
in the 10−10 mol/kg CGRP group was demonstrated up to 6 h
after injection. Arterial blood pressure was stable after injection
of CGRP.
Toshima et al. (1992) produced SAH in 41 rabbits by inject-
ing i.c. autologous blood. The animals were randomly assigned
to ﬁve groups and were sacriﬁced on day 2 post-SAH. Group 1
was the control group. Immediately prior to sacriﬁce, group 2
and 3 animals received a 2-h i.c. injection of vehicle or CGRP
(100 ng/kg/min), respectively. Group 4 and 5 animals received a
2-h i.v. injection of vehicle or CGRP (100 ng/kg/min), respec-
tively. The diameter of basilar artery in group 3 (i.c. CGRP) was
signiﬁcantly larger than that in group 2 (i.c. vehicle, p < 0.001).
Similarly, the diameter of basilar artery in group 5 (i.v. CGRP) was
signiﬁcantly greater than that in group 4 (i.v. vehicle, p < 0.01).
Although no signiﬁcant difference was observed in mean arterial
blood pressure between groups 2 and 3 (i.c. groups), there was a
signiﬁcant difference between i.v. groups 4 and 5 (lower in group 5,
p < 0.01).
Ahmad et al. (1996) implanted a CGRP slow-release tablet i.c.,
containing either 24 or 153 μg of human αCGRP, 24 h after
experimental SAH was induced in rabbits. Following implan-
tation, the CGRP level in the CSF remained elevated for 5
days. The implantation of the tablet almost completely amelio-
rated angiographic vasospasm. Moreover, no signiﬁcant systemic
hypotension or neurological adverse event was associated with the
treatment.
In a similar approach, Inoue et al. (1996) investigated the
efﬁcacy of a CGRP slow-release tablet for the prevention of cere-
bral vasospasm after SAH in monkeys. Experimental SAH was
produced by the method of Espinosa et al. (1984). The animal
underwent a right frontotemporal craniectomy under sterile con-
ditions. The duramaterwas opened, and the arachnoidmembrane
was microsurgically incised until the ipsilateral internal carotid
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artery (ICA) and proximal portions of the MCA and anterior
cerebral artery (ACA) were exposed. An autologous blood clot
(1 ml/kg) was then placed around the exposed arteries to produce
experimental SAH. For animals in the CGRP (n = 5) and placebo
(n = 5) groups, a total of three tablets (total drug 1200 μg) were
ipsilaterally placed under the frontal and temporal lobes at the
time of SAH production. In the control group, cerebral vasospasm
developed on day 7 (56% as an average of the ICA, MCA, and
ACA). In the CGRP group, vasospasm was signiﬁcantly amelio-
rated on average (75%, p< 0.02). TheCGRP concentration inCSF
was measurable only on day 7 for the CGRP group (6.5 nmol/L).
No signiﬁcant untoward reactions were recorded.
Toyoda et al. (2000) sought to determine whether adenovirus-
mediated gene transfer in vivo of CGRP, ameliorates cerebral
vasoconstriction after experimental SAH. Arterial blood was
injected into the cisterna magna of rabbits to mimic SAH 5 days
after injection of adenovirus or vehicle. After injection of aden-
ovirus (n = 8), there was a 400-fold increase in CGRP in CSF. In
rabbits treated with vehicle (controls, n = 8), basilar artery diam-
eter after SAH was 25% smaller than before SAH (p < 0.0005).
In rabbits treated with adenovirus, arterial diameter was simi-
lar before and after SAH. Furthermore, treatment of rabbits with
adenovirus after experimental SAH prevented spasm of the basilar
artery 2 days after SAH.
Likewise, Satoh et al. (2002) investigated whether a delayed
treatment with adenovirus encoding CGRP gene, 2 days after
experimental SAH, reduces cerebral vasospasm in a double-
hemorrhage model (on days 0 and 2) of severe vasospasm in dogs.
Severe vasospasm was observed in control SAH dogs (n = 12) on
day 7, and themean basilar artery diameterwas 53%of baseline. In
the group treated with adenovirus (n = 8), vasospasm was signif-
icantly reduced (the basilar artery diameter was 78% of baseline,
p < 0.05 compared with the control SAH group). High levels of
CGRP were measured in CSF from dogs that received adenovirus
(115-fold greater than baseline levels).
Intracisternal gene transfer of CGRP was initially thought to
be more useful than i.v. infusion, because the local gene transfer
might avoid systemic effects of CGRP and achieve its sustained
release into the central nervous system. However, there are several
concerns, such as the inﬂammatory process induced by aden-
ovirus, the difﬁculty in approaching the target cells in the presence
of a large subarachnoid blood clot, and its potential ability for
cancerous transformation of the affected cells.
EFFECTS OF CGRP ADMINISTRATION ON CEREBRAL VASOSPASM
AFTER SAH IN HUMANS (Table 2)
Juul et al. (1994) investigated the effect of i.v. CGRP infusion at
a rate of 0.6 μg/min in ﬁve patients with vasoconstriction in the
postoperative course after SAH, where the hemodynamic index
(ratio between middle cerebral and ICA mean velocities) was used
as an indicator of vasoconstriction. A signiﬁcant reduction was
found in the hemodynamic index during the CGRP infusion as
compared to that before infusion (4.3 vs. 6.2, p < 0.05). However,
no signiﬁcant change was observed in pulsatility index (another
indicator of vasospasm, equal to the difference between the systolic
and diastolic ﬂow velocities divided by the mean ﬂow veloc-
ity), blood pressure, or consciousness during CGRP infusion. A
signiﬁcant increase in heart rate was observed during the infusion,
while blood pressure remained unaltered.
Johnston et al. (1990) undertook a multicenter, randomized,
placebo-controlled trial to study the safety and efﬁcacy of i.v.
CGRP treatment to reverse neurological deﬁcits after surgical clip-
ping of a ruptured intracranial aneurysm. Patients were enrolled
if they had postoperative neurological deﬁcit. Patients received
CGRP or placebo in random order, 24 h apart. Fifteen patients
were eventually included in the study. Infusion started at a rate
sufﬁcient to deliver 0.035 μg/min CGRP, and was doubled every
10 min until either a clinical response was obtained or a maxi-
mum dose of 1.15 μg/min was reached at 1 h. If the neurological
deﬁcit had not deteriorated and the patient had no side-effects by
that time, the maximum infusion rate was continued for another
20 min. Regarding neurological changes according to the modi-
ﬁed Glasgow Coma Scale, ﬁve patients did not improve on either
treatment, one improved on both, eight improved on CGRP but
not on placebo, and one improved on placebo but not on CGRP.
Of the nine patients who showed a treatment preference, eight
(88.9%) favored CGRP (p < 0.05). The mean duration of neuro-
logical improvement was 25 min, after which patients returned to
their previous neurological status. There was a signiﬁcant decrease
in both systolic and diastolic blood pressures during the infusion
of CGRP.
A larger, multicenter, randomized controlled trial (European
CGRP in SAH study, 1992) investigated the effect of a post-
operative infusion of CGRP on outcome at 3 months. Patients
with aneurysmal SAH who underwent surgery entered the trial
if an ischemic neurological deﬁcit developed after the operation.
A total of 117 patients entered the study (62 patients received
CGRP and 55 standard management). The CGRP-treated patients
received the drug by i.v. infusion at a rate of 0.6 μg/min. If sys-
temic hypotension developed, the infusion rate was reduced to
0.45 μg/min, then to 0.3 μg/min, if the hypotension was still
apparent. CGRP treatment was given for at least 4 h; patients
who showed a satisfactory neurological response continued to
receive treatment for up to 10 days (minimum of 4 days). The
percentage of patients with a good outcome was slightly but not
signiﬁcantly higher in the CGRP than in the control group. The
relative risk of a bad outcome in CGRP-treated compared with
control patients was 0.88 (95% CI: 0.60−1.28). Interestingly, only
a third of patients randomized to receive CGRP completed treat-
ment, so two-thirds included in the treatment group for the
analyses had limited exposure to CGRP, mainly due to arterial
hypotension.
CONCLUSION
The pathogenesis of vasospasm after SAH is complex, multifacto-
rial, and incompletely understood. CGRP has shown promising
results both in vitro and in vivo, mainly in animal models of
experimental SAH. However, there is a lack of studies in humans.
Systemic hypotension induced by the i.v. administration of the
drug seems to be a serious problem. The encouraging results from
the i.c. application of CGRP in animals could warrant large studies
in humans with CGRP instillation into the subarachnoid space,
in order to avoid hypotension and achieve even more efﬁcient
dilatation of the cerebral arteries.
www.frontiersin.org November 2012 | Volume 3 | Article 135 | 11
“fendo-03-00135” — 2012/11/9 — 22:03 — page 12 — #12
Kokkoris et al. Role of CGRP in SAH
REFERENCES
Ahmad, I., Imaizumi, S., Shimizu,
H., Kaminuma, T., Ochiai, N.,
Tajima, M., et al. (1996). Develop-
ment of calcitonin gene-related pep-
tide slow-release tablet implanted in
CSF space for prevention of cerebral
vasospasm after experimental sub-
arachnoid haemorrhage. Acta Neu-
rochir. (Wien) 138, 1230–1240.
Aiyar, N., Disa, J., Stadel, J. M.,
and Lysko, P. G. (1999). Calci-
tonin gene-related peptide receptor
independently stimulates 3′,5′-cyclic
adenosinemonophosphate and Ca2+
signaling pathways. Mol. Cell.
Biochem. 197, 179–185.
Al-Tamimi, Y. Z., Orsi, N. M., Quinn,
A. C., Homer-Vanniasinkam, S., and
Ross, S. A. (2010). A review of
delayed ischemic neurologic deﬁcit
following aneurysmal subarachnoid
hemorrhage: historical overview, cur-
rent treatment, and pathophysiology.
World Neurosurg. 73, 654–667.
Alevizaki, M., Shiraishi, A., Rassool,
F. V., Ferrier, G. J., MacIntyre, I.,
and Legon, S. (1986). The calcitonin-
like sequence of the beta CGRP gene.
FEBS Lett. 206, 47–52.
Amara, S. G., Jonas, V., Rosenfeld,
M. G., Ong, E. S., and Evans, R.
M. (1982). Alternative RNA pro-
cessing in calcitonin gene expression
generates mRNAs encoding different
polypeptide products. Nature 298,
240–244.
Amin-Hanjani, S., Ogilvy, C. S., and
Barker, F. G. (2004). Does intracister-
nal thrombolysis prevent vasospasm
after aneurysmal subarachnoid hem-
orrhage? A meta-analysis. Neuro-
surgery 54, 326–334.
Arienta, C., Balbi, S., Caroli, M.,
and Fumagalli, G. (1991). Depletion
of calcitonin gene-related peptide
in perivascular nerves during acute
phase of posthemorrhagic vasospasm
in the rabbit. Brain Res. Bull. 27,
605–609.
Asano, T., and Matsui, T. (1999).
Antioxidant therapy against cere-
bral vasospasm following aneurysmal
subarachnoid hemorrhage. Cell Mol.
Neurobiol. 19, 31–44.
Benarroch, E. E. (2011). CGRP: sen-
sory neuropeptidewithmultiple neu-
rologic implications. Neurology 77,
281–287.
Brain, S. D., and Williams, T. J. (1988).
Substance P regulates the vasodila-
tor activity of calcitonin gene-related
peptide. Nature 335, 73–75.
Brain, S. D., and Williams, T. J. (1989).
Interactions between the tachykinins
and calcitonin gene-related peptide
lead to the modulation of oedema
formation and blood
ﬂow in rat skin. Br. J. Pharmacol. 97,
77–82.
Brain, S. D., Williams, T. J., Tippins, J.
R., Morris, H. R., and MacIntyre, I.
(1985). Calcitonin gene-related pep-
tide is a potent vasodilator. Nature
313, 54–56.
Breeze, A. L., Harvey, T. S., Bazzo,
R., and Campbell, I. D. (1991).
Solution structure of human calci-
tonin gene-related peptide by 1H
NMR and distance geometry with
restrained molecular dynamics. Bio-
chemistry 30, 575–582.
Brisman, J. L., Eskridge, J. M., and
Newell, D. W. (2006). Neurointer-
ventional treatment of vasospasm.
Neurol. Res. 28, 769–776.
Butt, E., Bernhardt, M., Smolenski, A.,
Kotsonis, P., Frohlich, L. G., Sick-
mann, A., et al. (2000). Endothe-
lial nitric-oxide synthase (type III) is
activated and becomes calcium inde-
pendent upon phosphorylation by
cyclic nucleotide-dependent protein
kinases. J. Biol. Chem. 275, 5179–
5187.
Carpenter, K. A., Schmidt, R., von
Mentzer, B., Haglund, U., Roberts, E.,
and Walpole, C. (2001). Turn struc-
tures in CGRP C-terminal analogues
promote stable arrangements of key
residue side chains. Biochemistry 40,
8317–8325.
Chiba, T., Yamaguchi, A., Yamatani, T.,
Nakamura, A., Morishita, T., Inui, T.,
et al. (1989). Calcitonin gene-related
peptide receptor antagonist human
CGRP-(8−37). Am. J. Physiol. 256,
E331–E335.
Chow, M., Dumont, A. S., and Kas-
sell, N. F. (2002). Endothelin receptor
antagonists and cerebral vasospasm:
an update. Neurosurgery 51, 1333–
1341.
Clark, J. F., and Sharp, F. R.
(2006). Bilirubin oxidation products
(BOXes) and their role in cerebral
vasospasm after subarachnoid hem-
orrhage. J. Cereb. Blood Flow Metab.
26, 1223–1233.
Conner, A. C., Hay, D. L., Howitt,
S. G., Kilk, K., Langel, U., Wheat-
ley, M., et al. (2002). Interaction of
calcitonin-gene-related peptide with
its receptors. Biochem. Soc. Trans. 30,
451–455.
Conner, A. C., Hay, D. L., Simms,
J., Howitt, S. G., Schindler, M.,
Smith, D. M., et al. (2005). A key
role for transmembrane prolines in
calcitonin receptor-like receptor ago-
nist binding and signalling: implica-
tions for family B G-protein-coupled
receptors. Mol. Pharmacol. 67,
20–31.
Conner, A. C., Simms, J., Barwell, J.,
Wheatley, M., and Poyner, D. R.
(2007). Ligand binding and activa-
tion of the CGRP receptor. Biochem.
Soc. Trans. 35, 729–732.
Crossman, D. C., Dashwood, M. R.,
Brain, S. D., McEwan, J., and Pear-
son, J. D. (1990). Action of calcitonin
gene-related peptide upon bovine
vascular endothelial and smooth
muscle cells grown in isolation and
co-culture. Br. J. Pharmacol. 99,
71–76.
Dennis, T., Fournier, A., Cadieux, A.,
Pomerleau, F., Jolicoeur, F. B., St
Pierre, S., et al. (1990). hCGRP8-
37, a calcitonin gene-related pep-
tide antagonist revealing calcitonin
gene-related peptide receptor hetero-
geneity in brain and periphery. J.
Pharmacol. Exp. Ther. 254, 123–128.
Dennis, T., Fournier, A., St Pierre, S.,
and Quirion, R. (1989). Structure-
activity proﬁle of calcitonin gene-
related peptide in peripheral and
brain tissues. Evidence for receptor
multiplicity. J. Pharmacol. Exp. Ther.
251, 718–725.
Disa, J., Parameswaran, N., Nambi, P.,
and Aiyar, N. (2000). Involvement of
cAMP-dependent protein kinase and
pertussis toxin-sensitive G-proteins
in CGRP mediated JNK activation
in human neuroblastoma cell line.
Neuropeptides 34, 229–233.
Dorhout Mees, S. M., Algra, A.,
Vandertop, W. P., van Kooten, F.,
Kuijsten, H. A., Boiten, J., et al.
(2012). Magnesium for aneurysmal
subarachnoid haemorrhage (MASH-
2): a randomised placebo-controlled
trial. Lancet 380, 44–49.
Dorsch, N. W. (1995). Cerebral arte-
rial spasm – a clinical review. Br. J.
Neurosurg. 9, 403–412.
Dreier, J. P., Major, S., Manning, A.,
Woitzik, J., Drenckhahn, C., Stein-
brink, J., et al. (2009). Cortical
spreading ischaemia is a novel pro-
cess involved in ischaemic damage
in patients with aneurysmal sub-
arachnoid haemorrhage. Brain 132,
1866–1881.
Duerrschmidt, N., Wippich, N.,
Goettsch, W., Broemme, H. J., and
Morawietz, H. (2000). Endothelin-1
induces NAD(P)H oxidase in human
endothelial cells. Biochem. Biophys.
Res. Commun. 269, 713–717.
Dumont, A. S., Dumont, R. J., Chow,
M. M., Lin, C. L., Calisaneller, T.,
Ley, K. F., et al. (2003). Cerebral
vasospasm after subarachnoid hem-
orrhage: putative role of inﬂamma-
tion. Neurosurgery 53, 123–133.
Dumont, Y., Fournier, A., St-Pierre,
S., and Quirion, R. (1997). A
potent and selective CGRP2 ago-
nist, [Cys(Et)2,7]hCGRPalpha: com-
parison in prototypical CGRP1 and
CGRP2 in vitro bioassays. Can. J.
Physiol. Pharmacol. 75, 671–676.
Edvinsson, L., Delgado-Zygmunt, T.,
Ekman, R., Jansen, I., Svendgaard, N.
A., and Uddman, R. (1990). Involve-
ment of perivascular sensory ﬁbers
in the pathophysiology of cerebral
vasospasm following subarachnoid
hemorrhage. J. Cereb. Blood Flow
Metab. 10, 602–607.
Edvinsson, L., Ekman, R., Jansen, I.,
McCulloch, J., Mortensen, A., and
Uddman,R. (1991). Reduced levels of
calcitonin gene-related peptide-like
immunoreactivity in human brain
vessels after subarachnoid haemor-
rhage. Neurosci. Lett. 121, 151–154.
Edvinsson, L., Fredholm, B. B.,
Hamel, E., Jansen, I., and Verrec-
chia, C. (1985). Perivascular peptides
relax cerebral arteries concomitant
with stimulation of cyclic adeno-
sine monophosphate accumulation
or release of an endothelium-derived
relaxing factor in the cat. Neurosci.
Lett. 58, 213–217.
Edvinsson, L., Gulbenkian, S., Bar-
roso, C. P., Cunha e Sa, M., Polak,
J. M., Mortensen, A., et al. (1998).
Innervation of the human mid-
dle meningeal artery: immunohisto-
chemistry, ultrastructure, and role of
endothelium for vasomotility. Pep-
tides 19, 1213–1225.
Egge, A., Waterloo, K., Sjoholm,
H., Solberg, T., Ingebrigtsen, T.,
and Romner, B. (2001). Prophylac-
tic hyperdynamic postoperative ﬂuid
therapy after aneurysmal subarach-
noid hemorrhage: a clinical, prospec-
tive, randomized, controlled study.
Neurosurgery 49, 593–605.
Espinosa, F., Weir, B., Overton,
T., Castor, W., Grace, M., and
Boisvert, D. (1984). A randomized
placebo-controlled double-blind trial
of nimodipine after SAH in mon-
keys. Part 1: clinical and radio-
logical ﬁndings. J. Neurosurg. 60,
1167–1175.
European CGRP in Subarachnoid
Haemorrhage Study Group. (1992).
Effect of calcitonin-gene-related pep-
tide in patients with delayed post-
operative cerebral ischaemia after
aneurysmal subarachnoid haemor-
rhage. European CGRP in Subarach-
noid Haemorrhage Study Group.
Lancet 339, 831–834.
Evans, B. N., Rosenblatt, M. I., Mnayer,
L. O., Oliver, K. R., and Dickerson,
I. M. (2000). CGRP-RCP, a novel
protein required for signal transduc-
tion at calcitonin gene-related pep-
tide and adrenomedullin receptors. J.
Biol. Chem. 275, 31438–31443.
Fassbender, K., Hodapp, B., Rossol, S.,
Bertsch, T., Schmeck, J., Schutt, S.,
Frontiers in Endocrinology | Neuroendocrine Science November 2012 | Volume 3 | Article 135 | 12
“fendo-03-00135” — 2012/11/9 — 22:03 — page 13 — #13
Kokkoris et al. Role of CGRP in SAH
et al. (2001). Inﬂammatory cytokines
in subarachnoid haemorrhage: asso-
ciation with abnormal blood ﬂow
velocities in basal cerebral arteries.
J. Neurol. Neurosurg. Psychiatry 70,
534–537.
Fassbender, K., Hodapp, B., Rossol,
S., Bertsch, T., Schmeck, J., Schutt,
S., et al. (2000). Endothelin-1 in
subarachnoid hemorrhage: an acute-
phase reactant produced by cere-
brospinal ﬂuid leukocytes. Stroke 31,
2971–2975.
Fernandez-Patron, C., Stewart, K. G.,
Zhang, Y., Koivunen, E., Radomski,
M. W., and Davidge, S. T. (2000).
Vascular matrix metalloproteinase-
2-dependent cleavage of calcitonin
gene-related peptide promotes
vasoconstriction. Circ. Res. 87,
670–676.
Ferro, A., Queen, L. R., Priest, R. M.,
Xu, B., Ritter, J. M., Poston, L., et al.
(1999). Activation of nitric oxide
synthase by beta 2-adrenoceptors in
human umbilical vein endothelium
in vitro. Br. J. Pharmacol. 126, 1872–
1880.
Freeland, K., Liu, Y. Z., and Latch-
man, D. S. (2000). Distinct signalling
pathwaysmediate the cAMP response
element (CRE)-dependent activation
of the calcitonin gene-related peptide
gene promoter by cAMP and nerve
growth factor. Biochem. J. 345(Pt 2),
233–238.
Frontera, J. A., Fernandez, A., Schmidt,
J. M., Claassen, J., Wartenberg, K. E.,
Badjatia, N., et al. (2009). Deﬁning
vasospasm after subarachnoid hem-
orrhage: what is the most clinically
relevant deﬁnition? Stroke 40, 1963–
1968.
Goretski, J., andHollocher, T. C. (1988).
Trapping of nitric oxide produced
during denitriﬁcation by extracellu-
lar hemoglobin. J. Biol. Chem. 263,
2316–2323.
Gray, D. W., and Marshall, I. (1992a).
Human alpha-calcitonin gene-
related peptide stimulates adenylate
cyclase and guanylate cyclase and
relaxes rat thoracic aorta by releasing
nitric oxide. Br. J. Pharmacol. 107,
691–696.
Gray, D. W., and Marshall, I. (1992b).
Nitric oxide synthesis inhibitors
attenuate calcitonin gene-related
peptide endothelium-dependent
vasorelaxation in rat aorta. Eur. J.
Pharmacol. 212, 37–42.
Grisham, M. B., Granger, D. N., and
Lefer, D. J. (1998). Modulation of
leukocyte-endothelial interactions by
reactive metabolites of oxygen and
nitrogen: relevance to ischemic heart
disease. Free Radic. Biol. Med. 25,
404–433.
Gulbenkian, S., Saetrum, O. O., Ekman,
R., Costa, A. N., Wharton, J., Polak,
J. M., et al. (1993). Peptidergic inner-
vation of human epicardial coronary
arteries. Circ. Res. 73, 579–588.
Haley, E. C. Jr., Kassell, N. F., Apperson-
Hansen, C., Maile, M. H., and
Alves, W. M. (1997). A randomized,
double-blind, vehicle-controlled trial
of tirilazad mesylate in patients
with aneurysmal subarachnoid hem-
orrhage: a cooperative study in
North America. J. Neurosurg. 86,
467–474.
Hay,D. L. (2007).Whatmakes a CGRP2
receptor? Clin. Exp. Pharmacol. Phys-
iol. 34, 963–971.
Hino,A., Tokuyama,Y.,Weir, B., Takeda,
J., Yano, H., Bell, G. I., et al. (1996).
Changes in endothelial nitric oxide
synthase mRNA during vasospasm
after subarachnoid hemorrhage
in monkeys. Neurosurgery 39,
562–567.
Hirashima, Y., Nakamura, S., Endo,
S., Kuwayama, N., Naruse, Y., and
Takaku, A. (1997). Elevation of
platelet activating factor, inﬂamma-
tory cytokines, and coagulation fac-
tors in the internal jugular vein of
patients with subarachnoid hemor-
rhage. Neurochem. Res. 22, 1249–
1255.
Hoare, S. R. (2005). Mechanisms of
peptide and nonpeptide ligand bind-
ing to Class B G-protein-coupled
receptors. Drug Discov. Today 10,
417–427.
Holzer, P. (2000). Local microcircula-
tory reﬂexes and afferent signalling
in response to gastric acid challenge.
Gut 47(Suppl. 4), iv46–iv48.
Horowitz, A.,Menice, C. B., Laporte, R.,
and Morgan, K. G. (1996). Mecha-
nisms of smooth muscle contraction.
Physiol. Rev. 76, 967–1003.
Huang, J., and van Gelder, J. M. (2002).
The probability of sudden death from
rupture of intracranial aneurysms:
a meta-analysis. Neurosurgery 51,
1101–1105.
Ignarro, L. J. (1990). Biosynthesis and
metabolism of endothelium-derived
nitric oxide. Annu. Rev. Pharmacol.
Toxicol. 30, 535–560.
Imaizumi, S., Shimizu, H., Ahmad,
I., Kaminuma, T., Tajima, M., and
Yoshimoto, T. (1996). Effect of calci-
tonin gene-relatedpeptide ondelayed
cerebral vasospasm after experimen-
tal subarachnoid hemorrhage in rab-
bits. Surg. Neurol. 46, 263–270.
Ingall, T., Asplund, K., Mahonen, M.,
and Bonita, R. (2000). A multi-
national comparison of subarach-
noid hemorrhage epidemiology in
the WHO MONICA stroke study.
Stroke 31, 1054–1061.
Inoue, T., Shimizu, H., Kaminuma,
T., Tajima, M., Watabe, K., and
Yoshimoto, T. (1996). Prevention
of cerebral vasospasm by calcitonin
gene-related peptide slow-release
tablet after subarachnoid hemor-
rhage in monkeys. Neurosurgery 39,
984–990.
Ishiguro, M., Murakami, K., Link, T.,
Zvarova, K., Tranmer, B. I., Morielli,
A. D., et al. (2008). Acute and chronic
effects of oxyhemoglobin on voltage-
dependent ion channels in cerebral
arteries. Acta Neurochir. Suppl. 104,
99–102.
Ishiguro, M.,Wellman, T. L., Honda, A.,
Russell, S. R., Tranmer, B. I., andWell-
man, G. C. (2005). Emergence of a
R-type Ca2+ channel (CaV 2.3) con-
tributes to cerebral artery constric-
tion after subarachnoid hemorrhage.
Circ. Res. 96, 419–426.
Jestaedt, L., Pham, M., Bartsch, A. J.,
Kunze, E., Roosen, K., Solymosi,
L., et al. (2008). The impact of bal-
loon angioplasty on the evolution
of vasospasm-related infarction
after aneurysmal subarachnoid
hemorrhage. Neurosurgery 62,
610–617.
Johnston, F. G., Bell, B. A., Robert-
son, I. J., Miller, J. D., Haliburn,
C., O’Shaughnessy, D., et al. (1990).
Effect of calcitonin-gene-related pep-
tide on postoperative neurological
deﬁcits after subarachnoid haemor-
rhage. Lancet 335, 869–872.
Jung,C. S., Iuliano, B.A.,Harvey-White,
J., Espey, M. G., Oldﬁeld, E. H.,
and Pluta, R. M. (2004). Association
between cerebrospinal ﬂuid levels of
asymmetric dimethyl-L-arginine, an
endogenous inhibitor of endothelial
nitric oxide synthase, and cerebral
vasospasm in a primatemodel of sub-
arachnoid hemorrhage. J. Neurosurg.
101, 836–842.
Juul, R., Aakhus, S., Bjornstad, K.,
Gisvold, S. E., Brubakk, A. O.,
and Edvinsson, L. (1994). Calcitonin
gene-related peptide (human alpha-
CGRP) counteracts vasoconstriction
in human subarachnoid haemor-
rhage. Neurosci. Lett. 170, 67–70.
Juul, R., Edvinsson, L., Gisvold, S.
E., Ekman, R., Brubakk, A. O.,
and Fredriksen, T. A. (1990). Cal-
citonin gene-related peptide-LI in
subarachnoid haemorrhage in man.
Signs of activation of the trigemino-
cerebrovascular system? Br. J. Neuro-
surg. 4, 171–179.
Juul, R., Hara, H., Gisvold, S. E.,
Brubakk, A. O., Fredriksen, T. A.,
Waldemar, G., et al. (1995). Alter-
ations in perivascular dilatory neu-
ropeptides (CGRP, SP, VIP) in the
external jugular vein and in the
cerebrospinal ﬂuid following sub-
arachnoid haemorrhage in man. Acta
Neurochir. (Wien) 132, 32–41.
Juvela, S. (2000). Plasma endothelin
concentrations after aneurysmal sub-
arachnoid hemorrhage. J. Neurosurg.
92, 390–400.
Kassell, N. F., Peerless, S. J., Durward,
Q. J., Beck, D. W., Drake, C. G.,
and Adams, H. P. (1982). Treatment
of ischemic deﬁcits from vasospasm
with intravascular volume expansion
and induced arterial hypertension.
Neurosurgery 11, 337–343.
Kasuya, H., Onda, H., Sasahara,
A., Takeshita, M., and Hori, T.
(2005). Application of nicardipine
prolonged-release implants: analysis
of 97 consecutive patients with acute
subarachnoid hemorrhage. Neuro-
surgery 56, 895–902.
Kim, Y. W., Lawson, M. F., and Hoh, B.
L. (2012). Nonaneurysmal subarach-
noid hemorrhage: an update. Curr.
Atheroscler. Rep. 14, 328–334.
Koide, M., Nystoriak, M. A., Brayden,
J. E., and Wellman, G. C. (2011).
Impact of subarachnoid hemorrhage
on local and global calcium sig-
naling in cerebral artery myocytes.
Acta Neurochir. Suppl. 110(Pt 1),
145–150.
Kosnik, E. J., and Hunt, W. E.
(1976). Postoperative hypertension
in the management of patients with
intracranial arterial aneurysms. J.
Neurosurg. 45, 148–154.
Kostron, H., Twerdy, K., and Grunert,
V. (1988). The calcium entry blocker
nimodipine improves the quality of
life of patients operated on for cere-
bral aneurysms. A 5-year follow-up
analysis. Neurochirurgia (Stuttg.) 31,
150–153.
Kraenzlin, M. E., Ch’ng, J. L., Mulderry,
P. K., Ghatei, M. A., and Bloom, S.
R. (1985). Infusion of a novel pep-
tide, calcitonin gene-related peptide
(CGRP) in man. Pharmacokinetics
and effects on gastric acid secretion
and on gastrointestinal hormones.
Regul. Pept. 10, 189–197.
Kwan, A. L., Lin, C. L., Chang,
C. Z., Winardi, D., Yen, C. P.,
Wu, S. C., et al. (2002). Oral
administration of an inhibitor of
endothelin-converting enzyme atten-
uates cerebral vasospasm following
experimental subarachnoid haemor-
rhage in rabbits. Clin. Sci. (Lond.)
103(Suppl. 48), 414S–417S.
Laufer, R., and Changeux, J. P. (1989).
Calcitonin gene-related peptide and
cyclic AMP stimulate phosphoinosi-
tide turnover in skeletal muscle cells.
Interaction between two secondmes-
senger systems. J. Biol. Chem. 264,
2683–2689.
www.frontiersin.org November 2012 | Volume 3 | Article 135 | 13
“fendo-03-00135” — 2012/11/9 — 22:03 — page 14 — #14
Kokkoris et al. Role of CGRP in SAH
Le Greves, P., Nyberg, F., Hokfelt, T.,
and Terenius, L. (1989). Calcitonin
gene-related peptide is metabolized
by an endopeptidase hydrolyzing
substance P. Regul. Pept. 25,
277–286.
Lennihan, L., Mayer, S. A., Fink, M.
E., Beckford, A., Paik, M. C., Zhang,
H., et al. (2000). Effect of hyper-
volemic therapy on cerebral blood
ﬂow after subarachnoid hemorrhage:
a randomized controlled trial. Stroke
31, 383–391.
Lin, C. L., Hsu, Y. T., Lin, T. K.,
Morrow, J. D., Hsu, J. C., Hsu. Y.
H., et al. (2006). Increased levels of
F2-isoprostanes following aneurys-
mal subarachnoid hemorrhage in
humans. Free Radic. Biol. Med. 40,
1466–1473.
Lynch, J. R., Wang, H., McGirt, M. J.,
Floyd, J., Friedman, A. H., Coon, A.
L., et al. (2005). Simvastatin reduces
vasospasm after aneurysmal sub-
arachnoid hemorrhage: results of a
pilot randomized clinical trial. Stroke
36, 2024–2026.
Macdonald, R. L., Higashida, R.
T., Keller, E., Mayer, S. A.,
Molyneux, A., Raabe, A., et al.
(2011). Clazosentan, an endothelin
receptor antagonist, in patients with
aneurysmal subarachnoid haemor-
rhage undergoing surgical clip-
ping: a randomised, double-blind,
placebo-controlled phase 3 trial
(CONSCIOUS-2). Lancet Neurol. 10,
618–625.
Macdonald, R. L., Kassell, N. F., Mayer,
S., Ruefenacht, D., Schmiedek, P.,
Weidauer, S., et al. (2008). Cla-
zosentan to overcome neurological
ischemia and infarction occurring
after subarachnoid hemorrhage
(CONSCIOUS-1): randomized,
double-blind, placebo-controlled
phase 2 dose-ﬁnding trial. Stroke 39,
3015–3021.
Macdonald, R. L.,Weir, B. K., Runzer, T.
D., Grace, M. G., Findlay, J. M., Saito,
K., et al. (1991). Etiology of cerebral
vasospasm in primates. J. Neurosurg.
75, 415–424.
Maggi, C. A., Rovero, P., Giuliani,
S., Evangelista, S., Regoli, D., and
Meli, A. (1990). Biological activity
of N-terminal fragments of calci-
tonin gene-related peptide. Eur. J.
Pharmacol. 179, 217–219.
Mayberg,M. R., Okada, T., and Bark, D.
H. (1990). The role of hemoglobin
in arterial narrowing after subarach-
noid hemorrhage. J. Neurosurg. 72,
634–640.
McCulloch, J., Uddman, R., Kingman,
T. A., and Edvinsson, L. (1986).
Calcitonin gene-related peptide:
functional role in cerebrovascular
regulation. Proc. Natl. Acad. Sci.
U.S.A. 83, 5731–5735.
McLatchie, L. M., Fraser, N. J., Main,
M. J., Wise, A., Brown, J., Thomp-
son, N., et al. (1998). RAMPs regulate
the transport and ligand speciﬁcity of
the calcitonin-receptor-like receptor.
Nature 393, 333–339.
Mee, E., Dorrance, D., Lowe, D., and
Neil-Dwyer, G. (1988). Controlled
study of nimodipine in aneurysm
patients treated early after subarach-
noid hemorrhage. Neurosurgery 22,
484–491.
Meens,M. J., Compeer,M. G., Hackeng,
T. M., van Zandvoort, M. A., Janssen,
B. J., and De Mey, J. G. (2010).
Stimuli of sensory-motor nerves ter-
minate arterial contractile effects of
endothelin-1 by CGRP and dissoci-
ation of ET-1/ET(A)-receptor com-
plexes. PLoS ONE 5, e10917. doi:
10.1371/journal.pone.0010917
Meens, M. J., Mattheij, N. J., van Loe-
nen, P. B., Spijkers, L. J., Lemkens,
P., Nelissen. J, et al. (2012). G-protein
betagamma subunits in vasorelaxing
and anti-endothelinergic effects of
calcitonin gene-related peptide. Br. J.
Pharmacol. 166, 297–308.
Mulderry, P. K., Ghatei, M. A., Spokes,
R. A., Jones, P. M., Pierson, A. M.,
Hamid, Q. A., et al. (1988). Dif-
ferential expression of alpha-CGRP
and beta-CGRP by primary sensory
neurons and enteric autonomic neu-
rons of the rat. Neuroscience 25,
195–205.
Neil-Dwyer, G., Mee, E., Dorrance, D.,
and Lowe, D. (1987). Early interven-
tion with nimodipine in subarach-
noid haemorrhage. Eur. Heart J.
8(Suppl. K), 41–47.
Nelson, M. T., Huang, Y., Brayden, J.
E., Hescheler, J., and Standen, N. B.
(1990). Arterial dilations in response
to calcitonin gene-related peptide
involve activation of K+ channels.
Nature 344, 770–773.
Nozaki, K., Kikuchi, H., and Mizuno,
N. (1989a). Changes of calcitonin
gene-related peptide-like immunore-
activity in cerebrovascular nerve
ﬁbers in the dog after experimentally
produced subarachnoid hemorrhage.
Neurosci. Lett. 102, 27–32.
Nozaki, K., Uemura, Y., Okamoto, S.,
Kikuchi,H., andMizuno,N. (1989b).
Relaxant effect of calcitonin gene-
related peptide on cerebral arterial
spasm induced by experimental sub-
arachnoid hemorrhage in dogs. J.
Neurosurg. 71, 558–564.
Ohkuma, H., Fujita, S., and Suzuki, S.
(2002). Incidence of aneurysmal sub-
arachnoid hemorrhage in Shimokita,
Japan, from 1989 to 1998. Stroke 33,
195–199.
Ohkuma, H., Tsurutani, H., and Suzuki,
S. (2001). Incidence and signiﬁcance
of early aneurysmal rebleeding before
neurosurgical or neurological man-
agement. Stroke 32, 1176–1180.
Padilla, B. E., Cottrell, G. S., Roost-
erman, D., Pikios, S., Muller, L.,
Steinhoff, M., et al. (2007). Endo-
thelin-converting enzyme-1 regulates
endosomal sorting of calcitonin
receptor-like receptor and beta-
arrestins. J. Cell Biol. 179, 981–997.
Petermann, J. B., Born, W., Chang, J.
Y., and Fischer, J. A. (1987). Identiﬁ-
cation in the human central nervous
system, pituitary, and thyroid of a
novel calcitonin gene-related peptide,
and partial amino acid sequence in
the spinal cord. J. Biol. Chem. 262,
542–545.
Pierce, K. L., Premont, R. T., and
Lefkowitz, R. J. (2002). Seven-
transmembrane receptors. Nat. Rev.
Mol. Cell Biol. 3, 639–650.
Pluta, R. M. (2005). Delayed cerebral
vasospasm and nitric oxide: review,
new hypothesis, and proposed treat-
ment. Pharmacol. Ther. 105, 23–56.
Pluta, R. M., Dejam, A., Grimes, G.,
Gladwin, M. T., and Oldﬁeld, E.
H. (2005). Nitrite infusions to pre-
vent delayed cerebral vasospasm in
a primate model of subarachnoid
hemorrhage. JAMA 293, 1477–1484.
Pluta, R. M., Thompson, B. G., Dawson,
T. M., Snyder, S. H., Boock, R. J., and
Oldﬁeld, E. H. (1996). Loss of nitric
oxide synthase immunoreactivity in
cerebral vasospasm. J. Neurosurg. 84,
648–654.
Polin, R. S., Bavbek, M., Shaffrey, M.
E., Billups, K., Bogaev, C. A., Kas-
sell, N. F., et al. (1998). Detection of
soluble E-selectin, ICAM-1, VCAM-
1, and L-selectin in the cerebrospinal
ﬂuid of patients after subarach-
noid hemorrhage. J. Neurosurg. 89,
559–567.
Poyner, D. (1995). Pharmacology of
receptors for calcitonin gene-related
peptide and amylin. Trends Pharma-
col. Sci. 16, 424–428.
Poyner, D. R., Sexton, P. M., Marshall,
I., Smith, D. M., Quirion, R., Born,
W., et al. (2002). International Union
of Pharmacology. XXXII. The mam-
malian calcitonin gene-related pep-
tides, adrenomedullin, amylin, and
calcitonin receptors. Pharmacol. Rev.
54, 233–246.
Queen, L. R., Xu, B., Horinouchi,
K., Fisher, I., and Ferro, A. (2000).
beta(2)-adrenoceptors activate nitric
oxide synthase in human platelets.
Circ. Res. 87, 39–44.
Quirion, R., Van Rossum, D., Dumont,
Y., St-Pierre, S., and Fournier, A.
(1992). Characterization of CGRP1
and CGRP2 receptor subtypes. Ann.
N. Y. Acad. Sci. 657, 88–105.
Sams-Nielsen, A., Orskov, C., and
Jansen-Olesen, I. (2001). Pharma-
cological evidence for CGRP uptake
into perivascular capsaicin sensitive
nerve terminals. Br. J. Pharmacol.
132, 1145–1153.
Santhanam,A.V., Smith, L.A.,Akiyama,
M., Rosales, A. G., Bailey, K. R.,
and Katusic, Z. S. (2005). Role of
endothelial NO synthase phosphory-
lation in cerebrovascular protective
effect of recombinant erythropoietin
during subarachnoid hemorrhage-
induced cerebral vasospasm. Stroke
36, 2731–2737.
Satoh, M., Perkins, E., Kimura, H.,
Tang, J., Chun, Y., Heistad, D.
D., et al. (2002). Posttreatment with
adenovirus-mediated gene transfer
of calcitonin gene-related peptide to
reverse cerebral vasospasm in dogs. J.
Neurosurg. 97, 136–142.
Seifert, V., Lofﬂer, B. M., Zimmer-
mann, M., Roux, S., and Stolke, D.
(1995). Endothelin concentrations in
patients with aneurysmal subarach-
noid hemorrhage. Correlation with
cerebral vasospasm, delayed ischemic
neurological deﬁcits, and volume
of hematoma. J. Neurosurg. 82,
55–62.
Sexton, P. M., Morﬁs, M., Tilakaratne,
N., Hay, D. L., Udawela, M.,
Christopoulos, G., et al. (2006).
Complexing receptor pharmacology:
modulation of family B G protein-
coupled receptor functionbyRAMPs.
Ann. N. Y. Acad. Sci. 1070, 90–104.
Sexton, P. M., Poyner, D. R., Simms,
J., Christopoulos, A., and Hay, D.
L. (2009). Modulating receptor func-
tion through RAMPs: can they repre-
sent drug targets in themselves? Drug
Discov. Today 14, 413–419.
Shibuya, M., Suzuki, Y., Sugita, K.,
Saito, I., Sasaki, T., Takakura, K.,
et al. (1992). Effect of AT877 on
cerebral vasospasm after aneurysmal
subarachnoid hemorrhage. Results
of a prospective placebo-controlled
double-blind trial. J. Neurosurg. 76,
571–577.
Steenbergh, P. H., Hoppener, J. W.,
Zandberg, J., Lips, C. J., and Jansz,
H. S. (1985). A second human cal-
citonin/CGRP gene. FEBS Lett. 183,
403–407.
Steenbergh, P. H., Hoppener, J. W.,
Zandberg, J., Visser, A., Lips, C. J.,
and Jansz, H. S. (1986). Structure
and expression of the human calci-
tonin/CGRP genes. FEBS Lett. 209,
97–103.
Struthers, A. D., Brown, M. J., Macdon-
ald, D. W., Beacham, J. L., Stevenson,
J. C., Morris, H. R., et al. (1986).
Frontiers in Endocrinology | Neuroendocrine Science November 2012 | Volume 3 | Article 135 | 14
“fendo-03-00135” — 2012/11/9 — 22:03 — page 15 — #15
Kokkoris et al. Role of CGRP in SAH
Human calcitonin gene related pep-
tide: a potent endogenous vasodila-
tor in man. Clin. Sci. (Lond.) 70,
389–393.
Sugawara, T., Ayer, R., Jadhav, V., Chen,
W., Tsubokawa, T., and Zhang, J. H.
(2011). Mechanisms of statin treat-
ment in cerebral vasospasm. Acta
Neurochir. Suppl. 110, 9–11.
Sullivan, G. W., Sarembock, I. J., and
Linden, J. (2000). The role of inﬂam-
mation in vascular diseases. J. Leukoc.
Biol. 67, 591–602.
Takizawa, T., Tada, T., Kitazawa, K.,
Tanaka, Y., Hongo, K., Kameko, M.,
et al. (2001). Inﬂammatory cytokine
cascade released by leukocytes in
cerebrospinal ﬂuid after subarach-
noid hemorrhage. Neurol. Res. 23,
724–730.
The ACROSS Group. (2000). Epidemi-
ology of aneurysmal subarachnoid
hemorrhage in Australia and New
Zealand: incidence and case fatal-
ity from theAustralasian Cooperative
Research on Subarachnoid Hemor-
rhage Study (ACROSS). Stroke 31,
1843–1850.
Thomas, J. E., Nemirovsky, A., Zel-
man, V., and Giannotta, S. L.
(1997). Rapid reversal of endothelin-
1-induced cerebral vasoconstriction
by intrathecal administration of
nitric oxide donors. Neurosurgery 40,
1245–1249.
Toda, N., Kawakami, M., and Yoshida,
K. (1991). Constrictor action of oxy-
hemoglobin inmonkey and dog basi-
lar arteries in vivo and in vitro. Am. J.
Physiol. 260, H420–H425.
Toshima, M., Kassell, N. F., Tanaka, Y.,
and Dougherty, D. A. (1992). Effect
of intracisternal and intravenous
calcitonin gene-related peptide on
experimental cerebral vasospasm in
rabbits. Acta Neurochir. (Wien) 119,
134–138.
Toyoda, K., Faraci, F. M., Watan-
abe, Y., Ueda, T., Andresen, J. J.,
Chu, Y., et al. (2000). Gene trans-
fer of calcitonin gene-related peptide
prevents vasoconstriction after sub-
arachnoid hemorrhage. Circ. Res. 87,
818–824.
Tran Dinh, Y. R., Debdi, M., Couraud,
J. Y., Creminon, C., Seylaz, J.,
and Sercombe, R. (1994). Time
course of variations in rabbit cere-
brospinal ﬂuid levels of calcitonin
gene-related peptide- and substance
P-like immunoreactivity in exper-
imental subarachnoid hemorrhage.
Stroke 25, 160–164.
Tseng, M. Y., Czosnyka, M., Richards,
H., Pickard, J. D., and Kirk-
patrick, P. J. (2005). Effects of
acute treatment with pravastatin
on cerebral vasospasm, autoregula-
tion, and delayed ischemic deﬁcits
after aneurysmal subarachnoid hem-
orrhage: a phase II randomized
placebo-controlled trial. Stroke 36,
1627–1632.
Tseng, M. Y., Hutchinson, P. J., Czos-
nyka, M., Richards, H., Pickard, J.
D., and Kirkpatrick, P. J. (2007).
Effects of acute pravastatin treatment
on intensity of rescue therapy, length
of inpatient stay, and 6-month out-
come in patients after aneurysmal
subarachnoid hemorrhage. Stroke 38,
1545–1550.
Uddman, R., Edvinsson, L., Ekblad,
E., Hakanson, R., and Sundler, F.
(1986). Calcitonin gene-related pep-
tide (CGRP): perivascular distribu-
tion and vasodilatory effects. Regul.
Pept. 15, 1–23.
van Gijn, J., Kerr, R. S., and Rinkel, G. J.
(2007). Subarachnoid haemorrhage.
Lancet 369, 306–318.
Vikman, P., Beg, S., Khurana, T. S.,
Hansen-Schwartz, J., and Edvins-
son, L. (2006). Gene expression and
molecular changes in cerebral arter-
ies following subarachnoid hemor-
rhage in the rat. J. Neurosurg. 105,
438–444.
Walker, C. S., Conner, A. C., Poyner,
D. R., and Hay, D. L. (2010).
Regulation of signal transduction
by calcitonin gene-related peptide
receptors. Trends Pharmacol. Sci. 31,
476–483.
Welty, T. E. (1987). Use of nimodipine
for prevention and treatment of cere-
bral arterial spasm in patients with
subarachnoid hemorrhage. Clin.
Pharm. 6, 940–946.
Wickman, G., Lan, C., and Vollrath,
B. (2003). Functional roles of the
Rho/Rho kinase pathway and protein
kinase C in the regulation of cere-
brovascular constriction mediated by
hemoglobin: relevance to subarach-
noid hemorrhage and vasospasm.
Circ. Res. 92, 809–816.
Wiley, J. W., Gross, R. A., and Macdon-
ald, R. L. (1992). The peptide CGRP
increases a high-threshold Ca2+ cur-
rent in rat nodose neurones via a
pertussis toxin-sensitive pathway. J.
Physiol. 455, 367–381.
Wilkins, R. H. (1990). Cerebral
vasospasm. Crit. Rev. Neurobiol. 6,
51–77.
Winn,H.R., Richardson,A. E., and Jane,
J. A. (1977). The long-term progno-
sis in untreated cerebral aneurysms:
I. The incidence of late hemorrhage
in cerebral aneurysm: a 10-year eval-
uation of 364 patients. Ann. Neurol.
1, 358–370.
Zwienenberg-Lee, M., Hartman, J.,
Rudisill, N., and Muizelaar, J. P.
(2006). Endovascular management
of cerebral vasospasm. Neurosurgery
59, S139–S147.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 23 July 2012; accepted: 24Octo-
ber 2012; published online: 15 November
2012.
Citation: Kokkoris S, Andrews P and
Webb DJ (2012) Role of calcitonin gene-
related peptide in cerebral vasospasm,
and as a therapeutic approach to sub-
arachnoid hemorrhage. Front. Endocrin.
3:135. doi: 10.3389/fendo.2012.00135
This article was submitted to Frontiers
in Neuroendocrine Science, a specialty of
Frontiers in Endocrinology.
Copyright © 2012 Kokkoris, Andrews and
Webb. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the origi-
nal authors and source are credited and
subject to any copyright notices concern-
ing any third-party graphics etc.
www.frontiersin.org November 2012 | Volume 3 | Article 135 | 15
